Study of DB8 imaging in estrogen receptor positive and negative breast cancer
Part of Cancer, Skin clinical trials.
This trial uses a special imaging agent called DB8 to see how it builds up in breast tumors. It compares results between women with estrogen receptor-positive and estrogen receptor-negative cancers to help improve detection.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be over 18 years old.
- You must have breast cancer and know your estrogen receptor status from a previous biopsy.
- Your blood counts, liver, and kidney function must be within certain limits (your doctor can check this).
- If you could become pregnant, you must have a negative pregnancy test and use birth control for at least 30 days after the study ends.
- You cannot be currently receiving chemotherapy or targeted therapy.
- You cannot have another type of cancer, an active autoimmune disease, or a serious infection.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new imaging agent that may help doctors see breast cancer more clearly. The test uses a radioactive tracer that attaches to a protein on cancer cells, which could help plan your treatment.
This study uses a radioactive tracer to see how much HER2 protein is on your breast cancer cells. The scan may help doctors understand the type of HER2 you have and choose the best treatment.
This study uses a special scan (molecular imaging) to see how well antibody-drug conjugates (ADCs) work in people with breast cancer. It may help doctors choose the right treatment for you.
This study tests a new imaging agent that targets a protein called ACE, which may be found in triple-negative breast cancer. The imaging will help doctors see the cancer more clearly and could aid in planning your treatment.
This study uses special PET/MRI scans to see how well breast cancer treatments are working. It aims to find better ways to monitor your cancer and guide your care.
This study tests whether using PET scans (a special imaging technique) to monitor how your HER2-positive breast cancer responds to treatment before surgery can help doctors choose the best treatment plan for you. The goal is to improve outcomes by personalizing therapy based on how your tumor responds.
Hear when a new Primary Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.